Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 599-603

  Garuti, Giancarlo ^a   Cellani, Fulvia ^b   Centinaio, Giovanna ^b   Montanari, Giuseppe ^a   Nalli, Giulio ^a   Luerti, Massimo ^b  

^a Lodi Hospital   (Italy)

^b NONE

Author keywords

Aromatase inhibitors; Breast cancer; Endometrial hyperplasia; Endometrium; Hysteroscopy; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; LIVER ENZYME; TAMOXIFEN;

AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DRUG SUBSTITUTION; ENDOMETRIAL DISEASE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CYTOLOGY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENZYME BLOOD LEVEL; EPITHELIUM HYPERPLASIA; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTEROSCOPY; MENARCHE; MENOPAUSE; MORBIDITY; MYOMETRIUM; ONSET AGE; PARITY; PREVALENCE; PRIORITY JOURNAL; RECURRENT CANCER; REFERENCE VALUE; REVERSAL REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUBSTITUTION THERAPY; THICKNESS; THROMBOPHLEBITIS; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS MYOMA;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 33750192472     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.04.004     Document Type: Article

References (27)

1. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Mannier A., et al. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the international letrozole breast cancer group. J Clin Oncol 19 (2001) 2596-2606
2. ATAC Trialists Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
3. Coombes R.C., Hall H., Gibson I.J., Paridaens R., Jassem J., Delozier T., et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
4. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 (2005) 1-10
5. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
6. Stearns V., and Gelmann E. Does tamoxifen cause cancer in humans?. J Clin Oncol 16 (1998) 779-792
7. Neven P., and Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Safety 22 (2000) 1-11
8. Bertelli G., Valenzano M., Costantini S., Rissone R., Angiolini C., Signorini A., et al. Limited value of sonohysterography for endometrial screening in asymptomatic postmenopausal patients treated with tamoxifen. Gynecol Oncol 78 (2000) 275-277
9. Garuti G., Cellani F., Grossi F., Colonnelli M., Centinaio G., and Luerti M. Saline infusion sonography and office hysteroscopy to assess endometrial morbidity associated with tamoxifen intake. Gynecol Oncol 86 (2002) 323-329
10. Develioglu O.H., Omak M., Bilgin T., Esmer A., and Tufckcy M. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 93 (2004) 328-335
11. Miller W.R. Aromatase inhibitors and breast cancer. Cancer Treat Rev 23 (1997) 171-187
12. Garuti G., Cellani F., Colonnelli M., Garzia D., Gonfiantini C., and Luerti M. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer. J Am Assoc Gynecol Laparosc 11 (2004) 62-67
13. Burkley C.H., and Fox H. Biopsy pathology of the endometrium. Biopsy Pathology Series vol. 14 (1989), Chapman and Hall Medical, London
14. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
15. Duffy S., and Jackson T. fewer endometrial abnormalities with anastrozole than tamoxifen: endometrial sub-protocol results from the ATAC early breast cancer trial in postmenopausal patients. Ann. Oncol. 13 suppl 5 (2002) [Abstr 139]
16. Garrone O., Mezi S., and Occelli M. Reversal of tamoxifen-induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study. Ann. Oncol. 14 suppl 4 (2003) [Abstr A22]
17. Duffy S., Jackson T.L., Lansdown M., Philips K., Wells M., Pollard S., et al. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod 20 (2005) 294-301
18. Duffy S., Jackson T.L., Lansdown M., Philips K., Wells M., Pollard S., et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 21 (2005) 545-553
19. Morales L., Timmerman D., Neven P., Konststantinovic M.L., Carbonez A., Van Huffel S., et al. Third generation aromatase inhibitors may prevent and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16 (2005) 70-74
20. Gerber B., Krause A., Reimer T., Mylonas I., Makovitzky J., Kundt G., et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 12 (2006) 1245-1250
21. Love C.D.B., and Dixon J.M. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. Breast 9 (2000) 156-157
22. Agorastos T., Vaitsi V., Pantazis K., Efstathiadis E., Vavilis D., and Bontis J.N. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 118 (2005) 239-240
23. Garuti G., Cellani F., Centinaio G., Sita G., Nalli G., and Luerti M. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women. Gynecol Oncol 98 (2005) 63-67
24. Goncalves M.A.G., Goncalves N.J., Matias M.M., Nazario A.C.P., Rodrigues De Lima G., and Baracat E.C. Hysteroscopic evaluation of the endometrium of postmenopausal patients with breast cancer before and after tamoxifen use. Int J Gynecol Obstet 66 (1999) 273-279
25. Bèrliere M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen; a need for systematic pretreatment screening. Obstet Gynecol 91 (1998) 41-44
26. Karlsson B., Granberg S., and Wikland M. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding. A Nordic multicenter study. Am J Obstet Gynecol 172 (1995) 489-492
27. Senkus-Konefka E., Konefka T., and Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 30 (2004) 291-301